Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: Treating "sick fat" through improving fat function with antidiabetes therapies

American Journal of Cardiology

Volumn 110, Issue SUPPL. 9, 2012, Pages 4B-12B

  Bays, Harold E ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BROMOCRIPTINE; CANNABINOID RECEPTOR ANTAGONIST; COLESEVELAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIPID; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NALTREXONE; PHENTERMINE; PIOGLITAZONE; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TOPIRAMATE; UNINDEXED DRUG;

ADIPOSE TISSUE; ADIPOSOPATHY; ARTICLE; BEHAVIOR MODIFICATION; BODY FAT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; ENDOCRINE DISEASE; EXERCISE; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84867487909     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.08.029     Document Type: Article

References (49)

1. Obesity and overweight Fact Sheet Number 311 World Health Organization; 2012 http://www.who.int/mediacentre/factsheets/fs311/en/ Accessed March 3, 2012
2. Diabetes Fact Sheet Number 312 World Health Organization; 2011 http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed March 3, 2012
3. H.E. Bays Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 57 2011 2461 2473
4. H.E. Bays, J.M. Gonzalez-Campoy, G.A. Bray, A.E. Kitabchi, D.A. Bergman, A.B. Schorr, H.W. Rodbard, R.R. Henry Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity Expert Rev Cardiovasc Ther 6 2008 343 368
5. H. Bays, H.W. Rodbard, A.B. Schorr, J.M. Gonzalez-Campoy Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk Curr Treat Options Cardiovasc Med 9 2007 259 271
6. H.E. Bays "Sick fat," metabolic disease, and atherosclerosis Am J Med 122 2009 S26 S37
7. H.E. Bays Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease Expert Rev Cardiovasc Ther 7 2009 1429 1445
8. H.E. Bays, K.M. Gadde Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity Drugs Today (Barc) 47 2011 903 914
9. H.E. Bays, B. Laferrere, J. Dixon, L. Aronne, J.M. Gonzalez-Campoy, C. Apovian, B.M. Wolfe Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract 63 2009 1285 1300
10. American Diabetes Association Executive summary: standards of medical care in diabetes - 2011 Diabetes Care 34 suppl 1 2011 S4 S10
11. H. Bays Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything Expert Rev Cardiovasc Ther 3 2005 393 404
12. A. Avogaro Postprandial glucose: marker or risk factor? Diabetes Care 34 2011 2333 2335
13. D. Aronson, E.J. Rayfield How hyperglycemia promotes atherosclerosis: molecular mechanisms Cardiovasc Diabetol 1 2002 1
14. K.K. Ray, S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, D. Preiss, S. Erqou, N. Sattar Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765-1672
15. H. Bays, L. Mandarino, R.A. DeFronzo Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 89 2004 463 478
16. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
17. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, W.R. Shanahan Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
18. H. Bays, C. Dujovne Anti-obesity drug development Expert Opin Investig Drugs 11 2002 1189 1204
19. H. Bays Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease Expert Rev Cardiovasc Ther 8 2010 1777 1801
20. Bays H, Schwartz S, Greenway F, Clapper B, Wang W, Kim D, Dunayevich E. Naltrexone SR/bupropion SR therapy in overweight/obese subjects with type 2 diabetes mellitus: effects on glycemic control after accounting for the influence of rescue medications for hyperglycemia. Guided Audio Poster Presentation (Abstract 1866). American Diabetes Association 71st Scientific Session, June 24-28, 2011, San Diego, California.
21. D. Hadziomerovic, B. Rabenbauer, L. Wildt Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women Fertil Steril 86 2006 651 657
22. D. Brustolim, R. Ribeiro-dos-Santos, R.E. Kast, E.L. Altschuler, M.B. Soares A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice Int Immunopharmacol 6 2006 903 907
23. H.E. Bays, R.B. Goldberg The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 14 2007 567 580
24. G. Anfossi, I. Russo, K. Bonomo, M. Trovati The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus Curr Vasc Pharmacol 8 2010 327 337
25. D. Sullivan, P. Forder, J. Simes, M. Whiting, L. Kritharides, A. Merrifield, M. Donoghoe, P.G. Colman, N. Graham, H. Haapamaki, A. Keech Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study Diabetes Res Clin Pract 94 2011 284 290
26. C. Beysen, E.J. Murphy, K. Deines, M. Chan, E. Tsang, A. Glass, S.M. Turner, J. Protasio, T. Riiff, M.K. Hellerstein Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study Diabetologia 55 2012 432 442
27. T. Suzuki, K. Oba, Y. Igari, K. Watanabe, N. Matsumura, S. Futami-Suda, M. Ouchi, K. Suzuki, K.I. Sekimizu, Y. Kigawa, H. Nakano Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study J Diabetes Complications 26 2012 34 39
28. M. Kobayashi, H. Ikegami, T. Fujisawa, K. Nojima, Y. Kawabata, S. Noso, N. Babaya, M. Itoi-Babaya, K. Yamaji, Y. Hiromine, M. Shibata, T. Ogihara Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin Diabetes 56 2007 239 247
29. J.R. Levy, D.M. Heuman, W.M. Pandak, W. Stevens Effect of bile acid composition and manipulation of enterohepatic circulation on leptin gene regulation Metabolism: Clin Exper 47 1998 285 291
30. M. Milanski, G. Degasperi, A. Coope, J. Morari, R. Denis, D.E. Cintra, D.M. Tsukumo, G. Anhe, M.E. Amaral, H.K. Takahashi, R. Curi, H.C. Oliveira Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity J Neurosci 29 2009 359 370
31. J.P. Thaler, C.X. Yi, E.A. Schur, S.J. Guyenet, B.H. Hwang, M.O. Dietrich, X. Zhao, D.A. Sarruf, V. Izgur, K.R. Maravilla, H.T. Nguyen, J.D. Fischer Obesity is associated with hypothalamic injury in rodents and humans J Clin Investig 122 2012 153 162
32. J.M. Gaziano, A.H. Cincotta, C.M. O'Connor, M. Ezrokhi, D. Rutty, Z.J. Ma, R.E. Scranton Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes Diabetes Care 33 2010 1503 1508
33. A.H. Cincotta, A.H. Meier Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 19 1996 667 670
34. H. Pijl, S. Ohashi, M. Matsuda, Y. Miyazaki, A. Mahankali, V. Kumar, R. Pipek, P. Iozzo, J.L. Lancaster, A.H. Cincotta, R.A. DeFronzo Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 23 2000 1154 1161
35. P. Kok, F. Roelfsema, M. Frolich, J. van Pelt, A.E. Meinders, H. Pijl Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women J Clin Endocrinol Metab 91 2006 3236 3240
36. A.H. Cincotta, A.H. Meier, M. Cincotta Jr Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opin Investig Drugs 8 1999 1683 1707
37. K. Berinder, T. Nystrom, C. Hoybye, K. Hall, A.L. Hulting Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy Pituitary 14 2011 199 207
38. D.S. Bell Why does quick-release bromocriptine decrease cardiac events? Diabetes Obes Metab 13 2011 880 884
39. P.A. Hollander Insulin detemir for the treatment of obese patients with type 2 diabetes Diabetes Metab Syndr Obes 5 2012 11 19
40. M. Carruthers, T.R. Trinick, E. Jankowska, A.M. Traish Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol 7 2008 30
41. T.D. Challa, N. Beaton, M. Arnold, G. Rudofsky, W. Langhans, C. Wolfrum Regulation of adipocyte formation by GLP-1/GLP-1R signaling J Biol Chem 287 2012 6421 6430
42. R. Nogueiras, D. Perez-Tilve, C. Veyrat-Durebex, D.A. Morgan, L. Varela, W.G. Haynes, J.T. Patterson, E. Disse, P.T. Pfluger, M. Lopez, S.C. Woods, R. DiMarchi Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity J Neurosci 29 2009 5916 5925
43. T. Vilsboll, M. Christensen, A.E. Junker, F.K. Knop, L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
44. J. Vendrell, R. El Bekay, B. Peral, E. Garcia-Fuentes, A. Megia, M. Macias-Gonzalez, J. Fernandez Real, Y. Jimenez-Gomez, X. Escote, G. Pachon, R. Simo, D.M. Selva Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance Endocrinology 152 2011 4072 4079
45. S.J. Kim, C. Nian, C.H. McIntosh GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene J Lipid Res 51 2010 3145 3157
46. P. Sathyanarayana, M. Jogi, R. Muthupillai, R. Krishnamurthy, S.L. Samson, M. Bajaj Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes Obesity 19 2011 2310 2315
47. D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig, S. Lehr, D.M. Ouwens, K. Eckardt, J.M. Kaufman, M. Ryden, S. Muller, F.G. Hanisch, J. Ruige Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
48. H. Bays From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus Curr Med Res Opin 25 2009 671 681
49. J. Bolinder, O. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, A.M. Langkilde, J. Sugg, S. Parikh Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031